Ligand Pharmaceuticals (LGND) Cash from Operations Growth (5y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Ligand Pharmaceuticals | 4.61 Bn | 3.83 Bn | 48.45 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 35.26% |
| Dec 31, 2025 | 143.44% |
| Sep 30, 2025 | 0.54% |
| Jun 30, 2025 | -8.31% |
| Mar 31, 2025 | -28.50% |
| Dec 31, 2024 | 42.52% |
| Sep 30, 2024 | 51.17% |
| Jun 30, 2024 | 23.68% |
| Mar 31, 2024 | -16.17% |
| Dec 31, 2023 | -24.36% |
| Sep 30, 2023 | -22.35% |
| Jun 30, 2023 | -14.88% |
| Mar 31, 2023 | -10.99% |
| Dec 31, 2022 | 11.30% |
| Sep 30, 2022 | -5.82% |
| Jun 30, 2022 | 2.72% |
| Mar 31, 2022 | 22.03% |
| Dec 31, 2021 | 8.10% |
| Sep 30, 2021 | 1.57% |
| Jun 30, 2021 | 14.46% |
| Mar 31, 2021 | -3.89% |
| Dec 31, 2020 | -47.66% |
| Sep 30, 2020 | 4.08% |
| Jun 30, 2020 | 19.40% |
| Mar 31, 2020 | 17.43% |
| Dec 31, 2019 | -22.12% |
| Sep 30, 2019 | -29.62% |
| Jun 30, 2019 | 2.79% |
| Mar 31, 2019 | 77.38% |
| Dec 31, 2018 | 22.04% |
| Sep 30, 2018 | 138.67% |
| Jun 30, 2018 | 60.40% |
| Mar 31, 2018 | 96.42% |
| Dec 31, 2017 | 80.77% |
| Sep 30, 2017 | 119.86% |
| Jun 30, 2017 | 84.75% |
| Mar 31, 2017 | 122.14% |
| Dec 31, 2016 | 21.69% |
| Sep 30, 2016 | 81.24% |
| Jun 30, 2016 | 26.89% |
| Mar 31, 2016 | 70.47% |
| Dec 31, 2015 | 72.25% |
| Sep 30, 2015 | 27.43% |